JAAD onlineOvicidal efficacy of high concentration dimeticone: A new era of head lice treatment
References (5)
- et al.
A highly efficacious pediculicide based on dimeticone: randomized observer blinded comparative trial
BMC Infectious Diseases
(2008) Current treatments for pediculosis capitis
Curr Opin Infect Dis
(2009)
Cited by (29)
Ectoparasites: Pediculosis and tungiasis
2020, Journal of the American Academy of DermatologyUpdate on human head lice
2019, SemergenEfficacy and safety of dimeticones in the treatment of epidermal parasitic skin diseases with special emphasis on tungiasis: an evidence-based critical review
2020, Brazilian Journal of Infectious DiseasesCitation Excerpt :If the application time was reduced to 10 min, 5–8% of the embryos survived and developed into adults. When 9–11 days old head lice eggs were treated with NYDA®, the efficacy of killing lice embryos was reduced to 97%.24,25 Anecdotal observations suggest that pubic lice are also highly susceptible to treatment with NYDA®.26
Update on parasitic dermatoses
2020, Anais Brasileiros de DermatologiaCitation Excerpt :The application should be repeated in seven to ten days. It has ovicidal action.24–26 Ivermectin topical 0.5% lotion was approved by the FDA in 2012 for the treatment of children aged 6 months or older.
Paediatrics: how to manage pediculosis capitis
2022, Drugs in Context
Supported by G. Pohl-Boskamp GmbH & Co. KG (Hohenlockstedt, Germany). Dr Heukelbach is a research fellow from the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq/Brazil). Dr Sonnberg was supported by the German Research Foundation, PhD program (Graduiertenkolleg) 793.
Conflicts of interest: Dr Heukelbach has been scientific consultant to G. Pohl-Boskamp GmbH & Co. KG, the manufacturer of NYDA. Dr Speare has been scientific consultant in the past to Emerald Forest Pharmaceuticals in trials on plant-based pediculicides, but currently has no links to the pharmaceutical industry. The other authors do not have any conflicts of interest to declare.